Victoria Divino

IQVIA (United Kingdom) — United Kingdom

Medicine · Health Sciences

20h-index1.1kcitations123works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(28), Influenza Virus Research Studies(18), Vaccine Coverage and Hesitancy(16), Diabetes Management and Research(14), Metabolism, Diabetes, and Cancer(13)

Publications123 total

An Evaluation of the Real-World Effectiveness of Immunoglobulin Therapy in Chronic Inflammatory Demyelinating Polyneuropathy
Neurology and Therapy·2025Open Access
Abstract 4369118: Lower Risk of Cardiovascular Events in Patients with Clinical Atherosclerotic Cardiovascular Disease Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-Clinical ASCVD Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Clinical Atherosclerotic Cardiovascular Disease Population)
Circulation·2025
Abstract 4369285: Lower Risk of Cardiovascular Events in Patients with Heart Failure Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-HF Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Heart Failure Population)
Circulation·2025
SAT-694 Association Between Engagement With The WeGoTogether Digital Self-support App And Weight Loss In A Real-world Setting
Journal of the Endocrine Society·2025Open Access
MON-716 Real-world Weight Loss Observed With Semaglutide And Tirzepatide In Patients With Overweight Or Obesity And Without Type 2 Diabetes
Journal of the Endocrine Society·2025Open Access
Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE)
Advances in Therapy·2025· 7 citedOpen Access
Real-World Weight Loss Among Patients Initiating Semaglutide 2.4 mg and Enrolled in WeGoTogether, a Digital Self-Support Application
Advances in Therapy·2025· 1 citedOpen Access
CO41 Real-world Clinical And Demographic Characteristics Associated With Progression To Type 2 Diabetes In Patients With Prediabetes
Value in Health·2025
HSD80 Assessing Real-World Dosing Patterns for Vesicular Monoamine Transporter-2 Inhibitors (VMAT2i), Valbenazine and Deutetrabenazine, Among Patients with Tardive Dyskinesia (TD) in a Nationwide US Claims Database
Value in Health·2025
732-P: Real-World Impact of Oral Semaglutide (SEMA) vs. DPP-4 Inhibitors on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes (T2D)—An Observational Study (PAUSE)
Diabetes·2025
Real-world Safety Assessment of Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with Subcutaneous IgPro20 (P10-11.023)
Neurology·2025
Once-Weekly Semaglutide Versus Sodium-Glucose Co-transporter 2 Inhibitors: Real-World Impact on Weight, HbA1c, and Healthcare Resource Utilization in Type 2 Diabetes (PAUSE)
Diabetes Therapy·2025· 1 citedOpen Access
A study looking at how missed somatropin injections affect growth in children with growth hormone deficiency: a plain language summary of publication
Therapeutic Advances in Endocrinology and Metabolism·2025· 1 citedOpen Access
Methodological standards for comparative effectiveness research: considerations for evidentiary review for medicare drug price negotiation
Expert Review of Pharmacoeconomics & Outcomes Research·2025
Development of cohort definitions and algorithms to identify patients with Lennox-Gastaut syndrome or Dravet syndrome from real-world administrative healthcare databases
Heliyon·2024· 1 citedOpen Access
Characteristics and Management of Uncontrolled Gout Prior to Pegloticase Therapy: A 2-year Claims Analysis
Rheumatology and Therapy·2024· 1 citedOpen Access
Retrospective Database Analysis of Liver-Related Clinical Events in Adult and Pediatric Patients with Alpha-1 Antitrypsin Deficiency in the United States
Hepatic Medicine Evidence and Research·2024Open Access
1884-LB: Real-World Impact of Once-Weekly Injectable Semaglutide (sema OW) vs. Sodium–Glucose Cotransporter 2 Inhibitors (SGLT2i) on HbA1c, Weight, and Health Care Resource Utilization (HCRU) Outcomes in Type 2 Diabetes (T2D)—An Observational Study (PAUSE)
Diabetes·2024
857-P: Real-World Impact of Once-Weekly Injectable Semaglutide on Weight, BMI, and HbA1c Outcomes in Type 2 Diabetes—An Observational Study (PAUSE)
Diabetes·2024
SA48 Methods to Account for the Impact of COVID-19 in Real-World Retrospective Studies of Economic Outcomes: A Targeted Literature Review
Value in Health·2024
page 1 of 7Next →

Frequent Co-authors

Mitch DeKoven(35), Stephen I. Pelton(7), J Mould-Quevedo(7), Vamshi Ruthwik Anupindi(7), Maarten J. Postma(7), Girishanthy Krishnarajah(6), Won Chan Lee(4), Kristina S. Boye(4), Michael Kleinrock(4), Rolin L. Wade(4), Emuella Flood(3), Matthew D. Rousculp(3), Stan L. Block(3), Matthew C. Hall(3), Parthiv J. Mahadevia(3), Drishti Shah(3), Kirsi Norrbacka(3), Satyin Kaura(3), Rajiv Mallick(3), Kellie Ryan(2)